youtube_live
Q3 2026 earnings • released • EPS beat +27,23% • Revenue beat +128,58%
See resultschevron_right
EDIT:NASDAQ
Editas Medicine Inc
2,50 US$
arrow_downward
-8,91%(-0,24) 1D
2,60 US$
arrow_upward
+3,79% (+0,095)todayPre-market
Closed: 10 ნოე, 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
2,70 US$
High
2,75 US$
Low
2,48 US$
Mkt. cap
384,72 მლნ.
Avg. vol.
2,33 მლნ.
Volume
2,63 ათ.
52-wk high
3,94 US$
52-wk low
1,66 US$
EPS
-0,62 US$
Beta
2,09
Shares outstanding
153,58 მლნ.
No. of employees
87
Open
2,70 US$
High
2,75 US$
Low
2,48 US$
Mkt. cap
384,72 მლნ.
Avg. vol.
2,33 მლნ.
Volume
2,63 ათ.
52-wk high
3,94 US$
52-wk low
1,66 US$
EPS
-0,62 US$
Beta
2,09
Shares outstanding
153,58 მლნ.
No. of employees
87
News stories
From web sources and news partners
TradingView
·
1 დღის წინ
Editas Medicine, Inc. reports results for the quarter ended September 30 - Earnings Summary
Zacks
·
2 დღის წინ
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
Investing.com
·
2 დღის წინ
Editas Medicine earnings beat by $0.04, revenue topped estimates
kare11.com
·
2 დღის წინ
Editas: Q3 Earnings Snapshot
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc